Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment
Annals of the Rheumatic Diseases · 2026-06 · 85 (6) · 1140-1155
DOI: 10.1016/j.ard.2026.02.003 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-06. Verfasst von Sofia Papanikolaou und 24 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology and Clinical Immunology, University of Crete Medical School, Iraklio, Greece; Institute for Bio-Innovation, Biomedical Sciences Research…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Biological Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RHEUMASEARCH Foundation for Research in Rheumatology.
Abstract (Originalsprache)
OBJECTIVES: Understanding the molecular events underlying systemic lupus erythematosus (SLE) onset and progression can facilitate early intervention strategies. We explored transcriptomic changes during progression from preclinical to clinical and advanced SLE, and assessed their potential reversibility by targeted agents. METHODS: This includes multicentre prospective study of individuals with nondiagnostic features suggestive of SLE. Baseline blood RNA-sequencing was performed in groups who progressed to classifiable SLE or not (n = 36 each), and compared with healthy (n = 42) and early SLE (n = 43). Transcriptome analysis included supervised methods, gene module-based clustering, and drug reversibility/repurposing pipelines with publicly available data. An independent at-risk cohort (n = 15 progressors, n = 20 nonprogressors) was used to validate molecular classifiers. RESULTS: At-risk individuals exhibited deregulated metabolic, cytokine signalling, haematologic, and stress-response pathways. Progressors vs nonprogressors showed heightened interferon (IFN)-alpha (α)/gamma (γ) and inflammatory cytokine activity, corroborated by Gene Set Enrichment Analysis and coexpression analysis, and intensified during SLE classification. Unsupervised modelling of gene module-eigengene patterns revealed molecular heterogeneity among progressors, differing in p53/insulin activity and Toll-like receptor (TLR) signalling. Importantly, we characterised a 17-gene susceptibility signature that predicted transition with an area under the curve 0.80 of the receiver operating characteris (95% CI: 0.65-0.94) in the external cohort. Analysis across the continuum-from healthy and at-risk states to early SLE and lupus nephritis-revealed stepwise upregulation of IFN-α/γ, haem metabolism, and oxidative phosphorylation pathways, with additional IFN-related genes activated in established disease. SLE susceptibility and progression signatures demonstrated in silico reversibility by anifrolumab and belimumab. CONCLUSIONS: IFN-α/γ and inflammatory cytokine signatures characterise evolving/early SLE, whereas amplification of IFN signalling and oxidative phosphorylation denotes severity. Blood molecular profiling may aid risk stratification and rationalise early biologic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rheumatology and Clinical Immunology, University of Crete Medical School, Iraklio, Greece; Institute for Bio-Innovation, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece.
- Rheumatology and Clinical Immunology, University of Crete Medical School, Iraklio, Greece.
- Rheumatology and Clinical Immunology, University of Crete Medical School, Iraklio, Greece; 4th Department of Internal Medicine, Hippokration University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greec…
- 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece; Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimen…
- Rheumatology and Clinical Immunology Unit-ERN ReCONNET, ASST Spedali Civili, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
- Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle, UK; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Förderung
- RHEUMASEARCH Foundation for Research in Rheumatology
Zitieren
APA
Papanikolaou, S., Emmanouilidou, E., Adamichou, C., Kalogiannaki, E., Nikolopoulos, D., Fredi, M., Carter, L. M., Tani, C., Kapsala, N., Repa, A., Malissovas, N., Garantziotis, P., Avgoustidis, N., Nikoleri, D., Banos, A., Vatsellas, G., Sidiropoulos, P., Konstantopoulos, D., Boumpas, D., …, & Bertsias, G. (2026). Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment. Annals of the Rheumatic Diseases, 85(6), 1140-1155. https://doi.org/10.1016/j.ard.2026.02.003
Vancouver
Papanikolaou S, Emmanouilidou E, Adamichou C, Kalogiannaki E, Nikolopoulos D, Fredi M, et al. Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment. Annals of the Rheumatic Diseases. 2026;85(6):1140-1155. doi:10.1016/j.ard.2026.02.003
BibTeX
@article{Papanikolaou2026,
author = {Papanikolaou, Sofia and Emmanouilidou, Evgenia and Adamichou, Christina and Kalogiannaki, Eleni and Nikolopoulos, Dionysios and Fredi, Micaela and Carter, Lucy Marie and Tani, Chiara and Kapsala, Noemin and Repa, Argiro and Malissovas, Nikos and Garantziotis, Panagiotis and Avgoustidis, Nestor and Nikoleri, Dimitra and Banos, Aggelos and Vatsellas, Giannis and Sidiropoulos, Prodromos and Konstantopoulos, Dimitrios and Boumpas, Dimitrios and Vital, Edward M and Andreoli, Laura and Mosca, Marta and Inês, Luís and Nikolaou, Christoforos and Bertsias, George},
title = {Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {6},
pages = {1140--1155},
doi = {10.1016/j.ard.2026.02.003}
}
EUVIMED